)
Mylan Pharmaceuticals Private Limited, Indian subsidiary of leading generic company - Mylan Inc., has launched the world’s first trastuzumab biosimilar in India.
The product will be marketed by Mylan under the brand name Hertraz, a biosimilar to Roche's Herceptin which is indicated for the treatment of breast cancer.
Trastuzumab is one of the five biologic products Mylan is developing in partnership with Biocon for the global marketplace. Mylan has exclusive commercialization rights for biosimilar trastuzumab in the US.
Heather Bresch, CEO, Mylan said, “Mylan is excited to offer Hertraz to the thousands of women in India suffering from metastatic breast cancer who are in need of a high quality, more affordable treatment option.”
For the period of 12 months, Trastuzumab had sales in India of approximately $21 million.
